Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

about

The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis.

P2860

Q48295398-A368D086-86D0-43C3-AE29-6A9EAFC03B62 Q54965977-99E850C5-6455-4861-8D4E-69C8B40A434C

P2860

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

Item

http://www.wikidata.org/entity/Q38716228

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

@en

type

Item

label

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

@en

prefLabel

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

@en

P1476

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors

@en

P2093

Bianca Gibelli

http://www.w3.org/2001/XMLSchema#string

Chiara Cella

http://www.w3.org/2001/XMLSchema#string

Chiara Grana

http://www.w3.org/2001/XMLSchema#string

Dario Ribero

http://www.w3.org/2001/XMLSchema#string

Dario Zerini

http://www.w3.org/2001/XMLSchema#string

Davide Ravizza

http://www.w3.org/2001/XMLSchema#string

Diana Martins

http://www.w3.org/2001/XMLSchema#string

Eleonora Pisa

http://www.w3.org/2001/XMLSchema#string

Emilio Bertani

http://www.w3.org/2001/XMLSchema#string

Francesca Spada

http://www.w3.org/2001/XMLSchema#string

P2860

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

Defining the role of mTOR in cancer

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?

Everolimus for advanced pancreatic neuroendocrine tumors.

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.

P2888

s11523-017-0506-5

P304

611-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-017-0506-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Fazio

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086099881

http://www.w3.org/2001/XMLSchema#string

P698

28634872

http://www.w3.org/2001/XMLSchema#string

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

about

P2860

P2860

Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698